Moleculin Biotech Inc reports results for the quarter ended June 30 - Earnings Summary

Moleculin Biotech

13/08/2026 22:46

Moleculin Biotech Inc MBRX.OQ reported a quarterly adjusted loss of $1.40​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-12.25.  The mean expectation of three analysts for the quarter was for a loss of $1.55 per share. Wall Street expected results to range from $-1.65 to $-1.45 per share.
Reported revenue was zero​; analysts expected zero. 
Moleculin Biotech Inc's reported EPS for the quarter was a loss of $1.40​.
The company reported a quarterly loss of $7.96 million.
Moleculin Biotech Inc shares had fallen by 81.3% this quarter and lost 84.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 6.4% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Moleculin Biotech Inc is $22.00, about 97.6% above its last closing price of $0.52
This summary was machine generated from LSEG data August 13 at 09:46 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.55
-1.40
Beat
Mar. 31 2026 
-1.66
-3.54
Missed
Dec. 31 2025 
-6.11
13.04
Beat
Sep. 30 2025 
-4.87
-17.00
Missed